Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIDEXX Laboratories Inc

IDEXX Laboratories Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
672.04 USD 0.00(0%)
Last update at 2026-11-03T21:00:00Z
VOLUME
1150703
Market Cap
41739.62M
P/E
49.99

Momentum Score

…

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
655.51
Low
681.50
High
52 Week Price Range
372.50
Low
583.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

IDEXX Laboratories develops and sells diagnostic instruments, consumable tests and practice-management software for companion animals, livestock and water quality testing. Long-term growth drivers include rising pet healthcare spending, recurring consumable and software revenue, increasing in-clinic diagnostic adoption and geographic expansion, which could support steady revenue growth. Investors may find the company attractive for its leading diagnostic franchises, high-margin recurring revenue streams and a track record of profitability.

Principal risks include dependence on veterinary and consumer spending patterns, competition and pricing pressure, execution risk in international expansion and exposure to regulatory or reimbursement changes that could affect diagnostic utilization.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
672.04
Dividend Yield
-
Revenue TTM
3724.85M
Revenue Per Share
44.83
Gross Profit TTM
2004.34M
Debt / Equity
0.64
ROE
71.91%
Net Debt
493.95M
ROCE
34.09%
Diluted EPS TTM
10.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 859.97M 902.65M 661.99M 522.22M 457.74M
Minority interest 0.00M 0.00M 0.35M 0.07M 0.02M
Net income 679.09M 744.85M 581.78M 427.72M 377.03M
Selling general administrative 326.25M 309.66M 300.83M 261.32M 244.94M
Selling and marketing expenses 524.50M 486.74M 434.44M 418.19M 387.41M
Gross profit 2004.34M 1889.43M 1571.04M 1365.55M 1241.54M
Reconciled depreciation 111.90M 104.60M 96.00M 88.01M 83.18M
Ebit 786.87M 827.43M 598.53M 464.83M 408.16M
Ebitda 898.76M 932.03M 694.52M 552.85M 491.33M
Depreciation and amortization 111.90M 104.60M 96.00M 88.01M 83.18M
Non operating income net other 1.06M 0.43M 0.59M 0.43M 1.15M
Operating income 898.76M 932.03M 694.52M 552.85M 491.33M
Other operating expenses 2468.56M 2283.33M 2012.13M 1854.06M 1721.91M
Interest expense 38.79M 29.37M 32.54M 30.63M 33.59M
Tax provision 180.88M 157.81M 79.85M 94.43M 80.69M
Interest income 1.06M 0.43M 0.59M 0.43M 1.15M
Net interest income -38.79M -29.37M -32.54M -30.63M -33.59M
Extraordinary items - - - - -2.10M
Income tax expense 180.88M 157.81M 79.85M 94.43M 80.69M
Total revenue 3367.32M 3215.36M 2706.66M 2406.91M 2213.24M
Total operating expenses 1105.57M 957.40M 876.52M 812.70M 750.21M
Cost of revenue 1362.99M 1325.93M 1135.62M 1041.36M 971.70M
Total other income expense net -38.79M -29.37M -32.54M -30.63M -33.59M
Net income from continuing ops 679.09M 744.84M 582.13M 427.79M 377.05M
Net income applicable to common shares 679.09M 744.85M 581.78M 427.72M 377.03M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3259.93M 2746.76M 2437.20M 2294.56M 1832.47M
Intangible assets 84.50M 97.67M 99.03M 52.54M 58.47M
Other current assets 203.59M 220.49M 173.82M 137.51M 124.98M
Total liab 1775.39M 2138.03M 1747.21M 1661.77M 1654.65M
Total stockholder equity 1484.53M 608.74M 689.99M 632.09M 177.47M
Deferred long term liab - 8.15M 8.94M 11.71M 33.02M
Other current liab 478.71M 433.66M 458.91M 415.65M 322.94M
Common stock 10.75M 10.72M 10.69M 10.65M 10.57M
Capital stock 10.75M 10.72M 10.69M 10.65M 10.57M
Retained earnings 4444.57M 3599.53M 2920.44M 2175.59M 1595.65M
Other liab - 106.59M 208.43M 220.51M 162.83M
Good will 365.96M 361.80M 359.35M 243.35M 239.72M
Other assets - 387.48M 893.88M 676.66M 240.19M
Cash 453.93M 112.55M 144.45M 383.93M 90.33M
Total current liabilities 951.55M 1235.80M 763.58M 582.76M 725.34M
Current deferred revenue 37.20M 37.94M 40.03M 42.57M 41.46M
Net debt 493.95M 1235.82M 779.25M 524.55M 897.35M
Short term debt 325.00M 653.98M 148.50M 49.99M 288.76M
Short long term debt 325.00M 653.98M 148.50M 49.99M 288.76M
Short long term debt total 947.88M 1348.37M 923.70M 908.48M 987.67M
Other stockholder equity -2899.59M -2923.72M -2187.65M -1500.54M -1382.56M
Property plant equipment - 649.47M 587.67M 555.17M 533.85M
Total current assets 1495.25M 1101.48M 955.65M 1062.74M 679.64M
Long term investments 56.19M 55.50M 13.35M 12.06M 13.66M
Net tangible assets - 149.27M 689.99M 336.20M -120.72M
Net receivables 457.44M 400.62M 368.35M 331.43M 269.31M
Long term debt 622.88M 694.39M 775.21M 858.49M 698.91M
Inventory 380.28M 367.82M 269.03M 209.87M 195.02M
Accounts payable 110.64M 110.22M 116.14M 74.56M 72.17M
Noncontrolling interest in consolidated entity - - - 0.71M 0.35M
Accumulated other comprehensive income -71.21M -77.80M -53.48M -53.62M -46.18M
Common stock total equity - 10.72M 10.69M 10.65M 10.57M
Retained earnings total equity - 3599.53M 2920.44M 2175.59M 1595.65M
Treasury stock - - -3570.69M -2799.89M -2600.54M
Non currrent assets other 448.48M 425.63M 397.37M 337.15M 299.04M
Non current assets total 1764.67M 1645.29M 1481.55M 1231.82M 1152.84M
Capital lease obligations 119.47M 121.66M 107.31M 94.77M 82.75M
Long term debt total - 694.39M 775.21M 858.49M 698.91M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -195.35M -292.97M -109.38M -205.53M 284.04M
Change to liabilities 3.47M 11.23M 0.98M 1.96M -0.17M
Total cashflows from investing activities -195.35M -292.97M -109.38M -205.53M 138.60M
Net borrowings 430.06M 23.50M -94.65M -10.43M -256.04M
Total cash from financing activities -370.94M -697.41M -248.42M -286.41M -597.80M
Change to operating activities -102.85M -137.52M -31.76M -34.79M -39.73M
Net income 679.09M 744.84M 582.13M 427.79M 377.05M
Change in cash -31.91M -239.47M 293.60M -33.47M -63.88M
Begin period cash flow 144.45M 383.93M 90.33M 123.79M 187.68M
End period cash flow 112.55M 144.45M 383.93M 90.33M 123.79M
Total cash from operating activities 542.98M 755.55M 648.06M 459.16M 400.08M
Depreciation 111.90M 104.60M 96.00M 88.01M 83.18M
Other cashflows from investing activities -46.51M -173.42M -2.42M -50.56M -29.68M
Change to inventory -121.73M -52.92M -18.89M -37.31M -25.62M
Change to account receivables -41.40M -33.14M -60.72M -22.47M -18.40M
Sale purchase of stock -830.32M -762.34M -203.42M -309.71M -378.69M
Other cashflows from financing activities 498.63M 114.92M 244.63M 133.58M 36.94M
Change to netincome 25.52M 148.22M 1.70M 48.32M 31.50M
Capital expenditures 148.84M 119.55M 107.63M 155.22M 122.94M
Change receivables -41.40M -33.14M -60.72M -22.47M -18.40M
Cash flows other operating -113.87M -62.70M 46.87M -47.15M -47.45M
Exchange rate changes - - - - -4.77M
Cash and cash equivalents changes -23.30M -234.84M 290.27M -32.78M -63.88M
Change in working capital -273.53M -137.52M -31.76M -104.97M -91.64M
Stock based compensation 49.77M 37.76M 30.95M 39.28M 25.16M
Other non cash items 10.82M 9.25M 8.83M 2.88M 5.13M
Free cash flow 394.15M 636.00M 540.44M 303.93M 277.15M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IDXX
IDEXX Laboratories Inc		 -
-%		 672.04 49.99 45.66 11.29 27.85 11.46 34.46
TMO
Thermo Fisher Scientific Inc		 15.69
2.30%		 698.34 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 2.14
0.94%		 230.11 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 23.25 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.81
3.50%		 22.35 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

IDEXX Laboratories Inc

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

One IDEXX Drive, Westbrook, ME, United States, 04092

207 556 0300

https://www.idexx.com

11000

Name Title Year Born
Mr. Jonathan J. Mazelsky Pres, CEO & Director 1961
Mr. Brian P. McKeon CFO, Exec. VP & Treasurer 1962
Mr. James F. Polewaczyk Exec. VP & Chief Commercial Officer 1964
Mr. Michael J. Lane Exec. VP and GM of Reference Laboratories & Information Technology 1968
Dr. Nimrata Khatra Hunt P.E., Ph.D. Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations 1968
Mr. John Hart Sr. VP of Worldwide Operations NA
Mr. Jeffery D. Chadbourne Sr. Director of Accounting & Financial Reporting 1976
Dr. Martin Smith Ph.D. Exec. VP & CTO 1968
Mr. Ken Grady Sr. VP & Chief Information Officer NA
Ms. Sharon E. Underberg Exec. VP, Gen. Counsel, & Corp. Sec. 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…